# Late-onset vascular and tumor complications after childhood brain radiotherapy: A rare case of dual sequelae

**Authors:** Quoc-Huy Ly, Shimon Garrel, Karthik Kanamalla, Armin Mahabadi, Daniel Masri

PMC · DOI: 10.1016/j.radcr.2026.01.063 · 2026-02-13

## TL;DR

A rare case shows a person who had childhood brain radiotherapy later developed both a meningioma and brain vasculopathy, emphasizing the need for long-term monitoring.

## Contribution

This case report highlights the rare co-occurrence of radiation-induced meningioma and vasculopathy after childhood brain radiotherapy.

## Key findings

- A patient developed late-onset complications 30 years after brain radiotherapy.
- Both radiation-induced meningioma and vasculopathy occurred in the same individual.
- Such dual sequelae are extremely rare and require lifelong surveillance.

## Abstract

Radiotherapy (RT) remains a mainstay of pediatric craniopharyngioma management. The long-term sequelae of intracranial RT are well documented and include radiation-induced brain tumors, cerebral vasculopathy, cognitive impairment, and an elevated risk of cerebrovascular accidents (CVAs). Patients treated for suprasellar or intrasellar tumors are at an increased risk of vasculopathy, likely because the Circle of Willis lies within the RT field. Here, we present a rare case of a patient who, 30 years after initial RT, developed multiple progressive late effects of cranial radiation, resulting in significant morbidity. To our knowledge, few case reports have described the concurrence of both a radiation-induced meningioma and radiation-induced vasculopathy, highlighting the rarity of this presentation and underscoring the importance of lifelong surveillance in pediatric brain tumor survivors especially within the RT treatment field.

## Linked entities

- **Diseases:** craniopharyngioma (MONDO:0018907), radiation-induced meningioma (MONDO:0011648)

## Full-text entities

- **Diseases:** cerebral vasculopathy (MESH:C566007), RIOV (MESH:D001157), meningioma (MESH:D008579), atherosclerotic (MESH:D050197), vascular (MESH:D057772), cerebrovascular toxicity (MESH:D002561), neurocognitive impairment (MESH:D019965), Moyamoya vasculopathy (MESH:D009072), ischemic attacks (MESH:D002546), infarct (MESH:D007238), cognitive impairment (MESH:D003072), lower extremity weakness (MESH:D020335), occlusive radiation vasculopathy (MESH:D011832), sequelae (MESH:D000094024), brain cancer (MESH:D001932), migraines (MESH:D008881), visual decline (MESH:D014786), Craniopharyngioma (MESH:D003397), headache (MESH:D006261), bitemporal hemianopsia (MESH:D006423), vascular and neoplastic complications (MESH:D019043), arterial dissection (MESH:D000094665), vasculopathy (MESH:D000090122), cancer (MESH:D009369), Down syndrome (MESH:D004314), vertigo (MESH:D014717), dysarthria (MESH:D004401), CVAs (MESH:D020521), autoimmune disease (MESH:D001327), Sellar mass (MESH:C536030), cranial nerve III palsy (MESH:D003389), cerebral vessel disease (MESH:D059345), RIM (MESH:C536266), stenosis (MESH:D003251), neurofibromatosis type 1 (MESH:D009456)
- **Chemicals:** Diamox (MESH:D000086)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12925087/full.md

---
Source: https://tomesphere.com/paper/PMC12925087